Tags: Drug.
Semuloparin (INN USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH). It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement as well as for patients undergoing chemotherapy.Like bemiparin semuloparin is classified as an ultra-LMWH because of its low molecular mass of 2000–3000 Daltons on average.